Logo do repositório
 
Publicação

Acromegaly and cardiovascular disease: mechanisms, clinical impact, and evolving management

2026-05-28Artigo de revisão Acesso aberto
Ver registo simples
dc.contributor.authorAraujo-Castro, Marta
dc.contributor.authorMarques, Pedro
dc.contributor.authorCardoso, Luis Miguel
dc.contributor.authorPascual-Corrales, Eider
dc.contributor.authorRefardt, Julie
dc.contributor.authorNeggers, Sebastian J. C. M. M.
dc.contributor.authorCassinello, José María Jiménez
dc.contributor.authorMarazuela, Mónica
dc.contributor.authorPuig-Domingo, Manel
dc.contributor.authorBiagetti, Betina
dc.date.accessioned2026-06-05T16:19:46Z
dc.date.available2026-06-05T16:19:46Z
dc.date.issued2026-05-28
dc.description.abstractCardiovascular disease is one of the most common and serious complications of acromegaly and a leading contributor to reduced life expectancy in affected individuals. This review examines the prevalence, mechanisms, diagnosis, and management of cardiovascular complications in patients with acromegaly. Growth hormone and insulin-like growth factor 1 excess promotes a range of cardiovascular disturbances, including structural heart changes, arrhythmias, vascular dysfunction, and an increased burden of traditional cardiovascular risk factors such as hypertension, diabetes, and dyslipidemia. Early recognition and targeted treatment of these complications are critical to reducing cardiovascular morbidity and mortality. While surgery and medical therapies for acromegaly aimed at normalizing hormone levels may lead to partial or full reversal of some cardiovascular alterations, many patients require continued management of comorbid conditions to control their overall cardiometabolic risk. Advances in diagnostic strategies and therapeutic options have contributed to improved survival, yet gaps remain in our understanding of how best to prevent or reverse cardiovascular damage in this population. Multidisciplinary care and individualized risk assessment are essential components of modern acromegaly management.eng
dc.identifier.doi10.1210/endrev/bnag011
dc.identifier.othere1a4e39e-b99c-4eaa-ab0f-3d5a4cee5c3a
dc.identifier.pmid42029663
dc.identifier.urihttp://hdl.handle.net/10400.14/57977
dc.identifier.wos001777087100001
dc.language.isoeng
dc.peerreviewedyes
dc.publisherEndocrine Society
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectAcromegalyeng
dc.subjectCardiovascular diseaseeng
dc.subjectCardiovascular risk factorseng
dc.subjectGrowth hormoneeng
dc.subjectManagementeng
dc.subjectMortalityeng
dc.titleAcromegaly and cardiovascular disease: mechanisms, clinical impact, and evolving management
dc.typereview article
dspace.entity.typePublication
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
151762449.pdf
Tamanho:
2.57 MB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

CBR - Contribuições em Revistas Científicas / Contribution to Journals